甲磺酸艾瑞布林（海乐卫）用于治疗乳腺癌。
Eribulin mesylate (Halaven) for breast cancer.
出版信息
Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1.
PMID:21502935
Abstract
Eribulin mesylate (Halaven-Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer. Prior therapy should have included an anthracycline and a taxane in either an adjuvant or metastatic setting. Other drugs used to treat anthracycline- and taxane-refractory metastatic breast cancer include capecitabine (Xeloda), gemcitabine (Gemzar, and others) and vinorelbine (Navelbine, and others).
摘要
甲磺酸艾瑞布林（商品名：Halaven - Eisai）已获美国食品药品监督管理局（FDA）批准，用于治疗既往接受过至少2种转移性癌症化疗方案的转移性乳腺癌患者。先前的治疗应在辅助治疗或转移性治疗中包含蒽环类药物和紫杉烷类药物。其他用于治疗对蒽环类药物和紫杉烷类药物耐药的转移性乳腺癌的药物包括卡培他滨（希罗达）、吉西他滨（健择等）和长春瑞滨（诺维本等）。
相似文献
1
Eribulin mesylate (Halaven) for breast cancer.
Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1.
2
Eribulin mesylate for the treatment of late-stage breast cancer.
Expert Opin Pharmacother. 2011 Dec;12(18):2883-90. doi: 10.1517/14656566.2011.637490. Epub 2011 Nov 17.
3
Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
Future Oncol. 2011 Mar;7(3):355-64. doi: 10.2217/fon.10.186. Epub 2011 Mar 7.
4
Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
Future Oncol. 2019 May;15(14):1641-1653. doi: 10.2217/fon-2018-0936. Epub 2019 Mar 20.
5
Eribulin: rediscovering tubulin as an anticancer target.
Clin Cancer Res. 2009 Jun 15;15(12):3903-5. doi: 10.1158/1078-0432.CCR-09-1023. Epub 2009 Jun 9.
6
Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Clin Ther. 2012 Jul;34(7):1467-73. doi: 10.1016/j.clinthera.2012.06.003. Epub 2012 Jun 25.
7
[Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
Nihon Yakurigaku Zasshi. 2011 Nov;138(5):209-17. doi: 10.1254/fpj.138.209.
8
Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
J BUON. 2016 Mar-Apr;21(2):375-81.
9
Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Expert Opin Pharmacother. 2016;17(4):589-600. doi: 10.1517/14656566.2016.1146683. Epub 2016 Feb 17.
10
Eribulin mesylate in breast cancer.
Womens Health (Lond). 2013 Nov;9(6):517-26. doi: 10.2217/whe.13.61.
引用本文的文献
1
Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression.
Vaccines (Basel). 2022 Jan 5;10(1):78. doi: 10.3390/vaccines10010078.
Zotero 插件